Stay updated on Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page.
Latest updates to the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page
- Check3 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. No substantive changes to the study details page.SummaryDifference0.0%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a Locations section listing Texas as a trial site, replacing the old Texas Locations label. The HHS Vulnerability Disclosure link was removed, and the page revision updated to v3.3.3.SummaryDifference0.2%
- Check53 days agoChange DetectedRevision indicator changed from v3.2.0 to v3.3.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check60 days agoChange DetectedThe funding-status notice about possible updates and operating status from a lapse in government funding has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check74 days agoChange DetectedAdministrative updates include a new Last Update Posted date of 2025-10-24 and minor textual edits; core study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check81 days agoChange DetectedThe study record now shows a primary completion/study completion date of 2027-10-30 and a recent update date of 2025-10-24.SummaryDifference0.3%
Stay in the know with updates to Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Combo in Relapsed Multiple Myeloma Clinical Trial page.